Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

BEERSE, Belgium--(BUSINESS WIRE) May 18, 2020 --The Janssen Pharmaceutical Companies of Johnson& Johnson announced today results reported for the first time from a Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials